Category list : European Medicines Agency (EMA)
Sort by: Newest first Oldest first A-Z Z-A
-
Stockpiles, shortages and supply chains: what a no-deal Brexit might mean for pharmacy Subscription
Fears of a no-deal Brexit impacting the UK’s drugs supply have been growing for some time, since the then health and social care secretary, Jeremy Hunt, admitted in January 2018 that the supply of some cancer drugs could be disrupted if the UK leaves the EU at the end of March 2019 with no agreement on a future relationship in place.
-
Impurity found in valsartan manufactured by second company in China, EMA says
Low levels of the potentially harmful impurity N-nitrosodimethylamine have been detected in batches of valsartan produced by a second pharmaceutical company, the European Medicines Agency has learnt.
-
Role of MHRA post-Brexit undecided, reveals government guidance
The future role of the UK’s medicines regulator is still “a matter for further discussion with the EU”, according to a document detailing the impact of a Brexit implementation period on the life science sector.
-
One extra cancer case per 5,000 patients taking varsartan, says EMA
The European Medicines Agency has issued an update on its ongoing review of the possible health effects in patients who have taken valsartan medicines containing a potentially harmful impurity.
-
EMA scales back functions and expects to lose a third of its staff
The European Medicines Agency has announced a temporary cutback in activities as it prepares for a workforce loss of up to 30% following its Brexit move to Amsterdam.
-
EMA recommends 16 medicines for approval, including four cancer drugs
Sixteen medicines have been recommended for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use at its July 2018 meeting.
-
'Patients could be seriously disadvantaged by Brexit, if we don’t get our act together'
UK drug regulator chair Sir Michael Rawlins on supplies of medicines after Brexit, POM-to-P switches and the legalisation of medical cannabis.
-
Brexit forum set up by community pharmacy negotiators
A Brexit forum representing community pharmacy and organisations involved in the medicines supply chain has been set up to share advice and information in the run-up to the UK leaving the EU.
-
Probable carcinogen in heart drug may have been present since 2012, reveals EMA
An impurity found in valsartan-containing medicines manufactured in China could have been present since 2012, according to the European Medicines Agency.
-
Government Brexit defeat in push to continue ties to European medicines regulations
The government lost its second vote on Brexit when MPs backed an amendment to its Trade Bill that instructs the government to make the UK’s participation in the European medicines regulatory network a negotiating priority when the UK leaves the EU.
